Epoch Investment Partners Inc. Has $35.06 Million Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Epoch Investment Partners Inc. increased its position in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) by 34.8% during the first quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 798,462 shares of the company’s stock after acquiring an additional 205,932 shares during the period. Epoch Investment Partners Inc. owned about 1.66% of Amphastar Pharmaceuticals worth $35,060,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also bought and sold shares of AMPH. Raymond James & Associates increased its stake in shares of Amphastar Pharmaceuticals by 75.7% in the fourth quarter. Raymond James & Associates now owns 92,659 shares of the company’s stock valued at $5,731,000 after buying an additional 39,916 shares during the period. McGlone Suttner Wealth Management Inc. bought a new position in Amphastar Pharmaceuticals during the 4th quarter worth approximately $28,000. China Universal Asset Management Co. Ltd. raised its holdings in Amphastar Pharmaceuticals by 339.5% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 5,542 shares of the company’s stock worth $343,000 after purchasing an additional 4,281 shares during the last quarter. International Assets Investment Management LLC acquired a new position in shares of Amphastar Pharmaceuticals in the 4th quarter worth approximately $8,610,000. Finally, Stratos Wealth Partners LTD. boosted its stake in shares of Amphastar Pharmaceuticals by 48.3% in the 4th quarter. Stratos Wealth Partners LTD. now owns 6,926 shares of the company’s stock valued at $428,000 after purchasing an additional 2,255 shares during the last quarter. Institutional investors and hedge funds own 65.09% of the company’s stock.

Analysts Set New Price Targets

A number of equities analysts recently weighed in on the stock. Piper Sandler reissued an “overweight” rating and set a $71.00 target price on shares of Amphastar Pharmaceuticals in a research note on Thursday, June 27th. Needham & Company LLC reissued a “hold” rating on shares of Amphastar Pharmaceuticals in a research note on Wednesday, May 22nd. Finally, StockNews.com raised Amphastar Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, May 13th. Two equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $64.67.

Insider Transactions at Amphastar Pharmaceuticals

In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,596 shares of the business’s stock in a transaction on Thursday, June 27th. The shares were sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the sale, the chief financial officer now owns 94,103 shares in the company, valued at approximately $3,851,635.79. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 3,596 shares of Amphastar Pharmaceuticals stock in a transaction dated Thursday, June 27th. The stock was sold at an average price of $40.93, for a total transaction of $147,184.28. Following the completion of the transaction, the chief financial officer now owns 94,103 shares in the company, valued at approximately $3,851,635.79. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, Director Floyd F. Petersen sold 3,000 shares of the business’s stock in a transaction that occurred on Monday, June 10th. The stock was sold at an average price of $41.40, for a total value of $124,200.00. Following the sale, the director now directly owns 78,409 shares of the company’s stock, valued at $3,246,132.60. The disclosure for this sale can be found here. Insiders have sold 7,596 shares of company stock valued at $313,544 over the last ninety days. 27.10% of the stock is owned by company insiders.

Amphastar Pharmaceuticals Stock Up 0.8 %

AMPH traded up $0.34 during midday trading on Friday, hitting $42.48. The company had a trading volume of 293,569 shares, compared to its average volume of 402,713. The company has a market capitalization of $2.08 billion, a price-to-earnings ratio of 14.70, a PEG ratio of 0.75 and a beta of 0.79. The stock’s 50 day moving average price is $40.53 and its 200 day moving average price is $44.86. The company has a quick ratio of 1.72, a current ratio of 2.18 and a debt-to-equity ratio of 0.88. Amphastar Pharmaceuticals, Inc. has a 52 week low of $36.56 and a 52 week high of $67.66.

Amphastar Pharmaceuticals (NASDAQ:AMPH) last posted its quarterly earnings results on Wednesday, May 8th. The company reported $0.93 earnings per share for the quarter, topping analysts’ consensus estimates of $0.73 by $0.20. Amphastar Pharmaceuticals had a return on equity of 29.17% and a net margin of 22.88%. The business had revenue of $171.84 million for the quarter, compared to the consensus estimate of $171.13 million. On average, research analysts anticipate that Amphastar Pharmaceuticals, Inc. will post 3.59 earnings per share for the current fiscal year.

About Amphastar Pharmaceuticals

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.